We recently published a list of Jim Cramer Discussed These 10 Stocks Recently. In this article, we are going to take a look ...

Viking Holdings shares dropped Tuesday as executives warned of macroeconomic "uncertainties" on the cruise operator's ...

Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing ...

Viking Therapeutics ( VKTX -0.30%) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...

Considering this and Viking's clinical trial advancements, is the stock a buy right now? Image source: Getty Images. First, let's back up and take a look at the company's story over the past year.

Viking Holdings beats Q4 earnings with a 20.5% sales rise, but shares drop. The company reports 88% of 2025 season bookings.

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

Viking stock soared a year ago on positive clinical trial data from its weight loss drug candidate. That candidate continues to progress, but Viking’s stock has tumbled from its peak.

The stock surged more than 120% in one trading session after Viking spoke about VK2735, a candidate that works in the same way as big pharma Eli Lilly's blockbuster drugs Mounjaro and Zepbound.